Browsing Tag
OPKO Health Inc.
2 posts
Entera Bio’s next big opportunity: Can its oral osteoporosis treatment transform a market dominated by injections?
Entera Bio's EB613 osteoporosis results strengthen its Phase 3 outlook. Explore the $275M financing, stock reaction and commercial potential.
OPKO Health (Nasdaq: OPK) raises $125m against mazdutide royalties as GLP-1 financing strategy deepens
OPKO Health raises $125 million against mazdutide royalties. Read how the KKR-linked financing reshapes OPK’s GLP-1 capital strategy.